Liminal BioSciences Inc. Common Shares
LMNL
LMNL was delisted on the 25th of September, 2023.
18 hedge funds and large institutions have $405K invested in Liminal BioSciences Inc. Common Shares in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
4,300% more call options, than puts
Call options by funds: $44K | Put options by funds: $1K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6% more funds holding
Funds holding: 17 → 18 (+1)
14% less capital invested
Capital invested by funds: $472K → $405K (-$66.5K)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$191K |
| 2 |
Morgan Stanley
New York
|
+$55K |
| 3 |
ECM
Estabrook Capital Management
New York
|
+$7.49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.34K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$56.3K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$27K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$13.1K |
| 4 |
VF
Virtu Financial
New York
|
-$11.6K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$6.76K |
LMNL Hedge Fund Activity: Q4 2021 in Review
18 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Liminal BioSciences Inc. Common Shares (LMNL) for Q4 2021, worth a combined $405K — down 14% from $472K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LMNL positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $191K. The largest seller was Citadel Advisors, exiting entirely with an estimated $56.3K sold.
- 18 institutional investors held Liminal BioSciences Inc. Common Shares (LMNL) as of Q4 2021, up from 17 in Q3 2021.
- Funds reported $405K of Liminal BioSciences Inc. Common Shares stock for Q4 2021, down 14% quarter-over-quarter.
- 4 funds opened new Liminal BioSciences Inc. Common Shares positions in Q4 2021 and 3 closed out, a net change of +1 holder.
- The largest Liminal BioSciences Inc. Common Shares buyer in Q4 2021 was Renaissance Technologies, an estimated $191K added.
- The largest Liminal BioSciences Inc. Common Shares seller in Q4 2021 was Citadel Advisors, an estimated $56.3K sold.
Based on aggregated 13F filings for Q4 2021.